21 results
8-K/A
EX-99.2
ELTX
Elicio Therapeutics Inc.
11 Aug 23
Elicio Therapeutics, Inc. Financial Statements
9:13pm
, Santa Clara, California (“SVB”) was closed by the California Department of Financial Protection and Innovation, which appointed the FDIC as receiver
8-K/A
EX-99.1
ELTX
Elicio Therapeutics Inc.
11 Aug 23
Elicio Therapeutics, Inc. Financial Statements
9:13pm
”) was closed by the California Department of Financial Protection and Innovation, which appointed the FDIC as receiver. According to the FDIC press release
8-K
EX-99.3
ELTX
Elicio Therapeutics Inc.
2 Jun 23
Angion Biomedia Corp. Announces 1-for-10 Reverse Stock Split
4:36pm
tumor-targeted immune responses of increased magnitude, function, and durability.
The second advance is the clinical innovation of administering ELI … innovation to develop and maintain its competitive position. Elicio seeks to protect and maintain the confidentiality of proprietary information
8-K
EX-99.4
ELTX
Elicio Therapeutics Inc.
2 Jun 23
Angion Biomedia Corp. Announces 1-for-10 Reverse Stock Split
4:36pm
of the Biologics Price Competition and Innovation Act of 2009 (BPCIA) created an abbreviated pathway for the approval of biosimilar and interchangeable
424B3
k2dtd oav86evj
28 Apr 23
Prospectus supplement
4:07pm
S-4/A
EX-10.26
5n9puh 6bby37t
29 Mar 23
Registration of securities issued in business combination transactions (amended)
5:29pm
S-4/A
t76 a9g50111
29 Mar 23
Registration of securities issued in business combination transactions (amended)
5:29pm
10-K
tox52t dmxic9p4us
30 Mar 21
Annual report
5:00pm
424B4
qthqtgfpw s7
5 Feb 21
Prospectus supplement with pricing info
5:12pm
DRS/A
epaavw1tq 95576
15 Dec 20
Draft registration statement (amended)
12:00am